2025 ASTRO Annual Refresher Course – American Society for Radiation Oncology (ASTRO)
Learn more about the 2025 ASTRO Annual Refresher Course.
Related Articles
Adjuvant Cemiplimab Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.
India tops Commonwealth nations in cancer cases: Lancet
NEW DELHI: Cancer incidence rates in India are substantially higher than any other Commonwealth nation, which saw an increase in cancer diagnosis by 35% between
Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL
John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.
How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.
Zanubrutinib Plus Obinutuzumab/Venetoclax Associated With Durable uMRD4 Outcomes in Treatment-Naive CLL
Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.
Celecoxib Improves DFS, OS in ctDNA-Positive Colon Cancer
Celecoxib plus chemo can improve outcomes over placebo plus chemo in patients with colon cancer who have ctDNA-positive plasma after surgery.
Personalizing pain relief for cancer patients
A team of Ohio State experts has come together to reduce cancer patients’ pain, leading to improved treatment and quality of life.
Ide-Cel and KarMMa-3: Exploring the latest CAR T Data for Early R/R MM
The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed R/R MM, with a median…
Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer
Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.
A Close Look at Clinical Trials in Oncology and Beyond: Incorporating Into Standard Care
In this episode, experts discuss the importance of integrating clinical trials as a standard of care, particularly in the realm of oncology.